Swiss pharma giant Roche Holding AG RHHBY reported sales of CHF 46.5 billion in the first nine months of 2026, up 1% year over year. Sales were up 6% at constant exchange rates (CER). The company reports under two divisions — Pharmaceuticals and Diagnostics. All growth rates mentioned below are on a year-over-year basis and at CER. Sales in the Pharmaceuticals Division grew 7% in the first nine months to CHF 36.2 billion, driven by strong growth in demand for its key drugs — Xolair (allergic asthma, chronic hives, food allergies), Hemlibra (haemophilia A), Ocrevus (multiple sclerosis), Phesgo (breast cancer) and Vabysmo (severe eye diseases). The Diagnostics division's sales were up 4% to CHF 10.
Nous affichons publiquement l'idee principale. Creez un compte gratuit pour lire l'article complet, l'enregistrer, le commenter et le relier au contexte marches et OSINT.